Rationalized Approach for Formulation and Optimization of Ebastine Microemulsion Using Design Expert for Solubility Enhancement by Mehetre, Jaswandi et al.
Mehetre et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):386-397 
ISSN: 2250-1177                                                                                   [386]                                                                                     CODEN (USA): JDDTAO 
Available online on 15.06.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                    Research Article 
Rationalized Approach for Formulation and Optimization of Ebastine 
Microemulsion Using Design Expert for Solubility Enhancement  
Mehetre Jaswandi1*, Vimal Kumar1, Mehta Tejal2, Gohel Mukesh3 Surti Naazneen4 
1 ITM School of Pharmacy, Gujarat Technological University, Gujarat, India 
2  Institute of Pharmacy, Nirma University, Gujarat, India 
3 Anand Pharmacy College, Gujarat Technological University, Gujarat, India 
4 Babaria Institute of Pharmacy, Gujarat Technological University, Gujarat, India 
 
ABSTRACT 
Ebastine is available as an oral antihistamine formula for allergic disorders such as tablets and syrup. Oral ebastine causes unfavorable effects 
on heart like QT prolongation, severe gastric distress, decreased tear production, resulting in dryness of the ocular surface, which exacerbates 
ocular discomfort and increasing susceptibility of eye to irritation. To avoid systemic side effects and ocular discomfort, topical ocular therapy 
could prove to be superior to systemic therapy in treating ocular allergies. Hence, topical formulation was developed to achieve onsite exposure 
of ebastine for ocular allergies. Moreover, conjunctiva is more accessible to hydrophilic molecules than lipophilic molecules. This creates 
challenge for a lipophilic molecule such as ebastine for topical ocular development. Successful dissolution of ebastine in o/w microemulsion 
allows its use in more convenient soluble form. Initially, solubility of drug in various oils, surfactant and cosurfactant was determined, followed 
by pseudo-ternary phase diagram to find microemulsion area. The D-optimal mixture design was employed for optimization of formulation. The 
optimized microemulsion formulation was characterized for its transparency, drug content, droplet size, zeta potential, viscosity, isotonicity, 
osmolarity and surface tension etc. The optimum physicochemical properties were observed to be eye-fitting. Carboxy methyl cellulose and 
sodium hyaluronate were used as gelling agents at different concentrations to increase residential time at the site of action. In vitro drug 
release study revealed that ebastine release from microemulsion gel in a sustained manner up to 24 hrs. for the purpose of providing prolonged 
therapy for ocular allergy. Hence, prepared microemulsion had great potential as an alternative to customary oral formulations of poorly 
soluble drug. 
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INTRODUCTION 
Ocular drug delivery generally involves the delivery of 
therapeutically active agents into anterior and posterior 
segments of the eye. Conjunctivitis is a prevalent disease all 
over the world especially higher rate of infection was found 
in developing countries. Conjunctivitis may be bacterial, viral 
or chlamydial, allergic. Allergic conjunctivitis is caused by an 
allergen-induced inflammatory response in which allergens 
interact with IgE bound to sensitized mast cells resulting in 
the clinical ocular allergic expression1. A major problem in 
ocular therapeutics is the attainment of an optimal drug 
concentration at the site of action. Poor bioavailability of 
drugs from ocular dosage forms is mainly due to the 
precorneal loss factors which include tear dynamics, non-
productive absorption, transient residence time in the cul-
de-sac and relative impermeability of the corneal epithelial 
membrane2. Additionally, most drugs with ocular therapeutic 
potential have the problem of poor solubility and hence less 
bioavailability. To overcome it, various technological 
strategies are reported in the literature including 
micronization, nanosuspension, polymeric micelles and 
cyclodextrin based formulation3. 
Among various approaches, microemulsion are promising 
alternative to enhance the ocular bioavailability of drugs by 
improved ocular retention, increased corneal drug 
absorption and reduced systemic side effects and maintain 
the simplicity and convenience of the dosage form as eye 
drops4. Microemulsions are thermodynamically stable, 
surfactant-cosurfactant based system, form at low interfacial 
tension and exhibit high solubilizing potential for 
hydrophobic drugs. They are good alternative for ophthalmic 
delivery as it offers the pseudo plastic rheology with 
increased viscosity after application and increased ocular 
retention and possibility of releasing drug in sustained and 
controlled way, increased shelf life, lastly reducing dose and 
dosing frequency5. 
Ebastine is official in British pharmacopoeia. It is a second-
generation H1 receptor antagonist, chemically 1-[4-(1,1-
dimethyl ethyl) phenyl]-4-[4-(diphenyl methoxy) piperidin-
1-yl] butan-1-one indicated for various allergic 
manifestations of skin, nasal and ocular site by oral route6,7,8. 
Oral administration of antihistamine leads to dryness of eye 
which affects physiology of tear film9. A successful attempt is 
made to prepared low dose and low concentration of the 
surfactant based Ophthalmic ebastine microemulsion 
formulations employing the concept of design of experiment 
with goal of solubility enhancement thereby boosting 
bioavailability due to site specificity as well reduces systemic 
side effects and hence will enhance the patient compliance.  
MATERIALS AND METHODS 
Ebastine was procured as a gift sample from, Bal Pharma Pvt. 
Ltd, Bommasandra, Bangalore, India. Campul MCM EP, 
Labrasol. Labrafac, Cremophor EL, Lauroglycol FCC was 
generously supplied by Gattefosse, Saint-Priest, France. Oleic 
acid, Ethyl oleate, Isopropyl palmitate, Arachis oil, Linseed 
oil, light liquid paraffin was purchased from Yarrow 
chemicals Pvt. Ltd Mumbai, India. Propylene glycol, 
Polyethyleneglycol 400 (PEG-200), Sorbian monooleate 
(Span-80), Polyoxyethylenesorbitan monooleate (Tween-
80), Polyoxyethylenesorbitan monolaurate (Tween-20), 
Isopropyl alcohol, butanol was purchased form S.D. Fine 
chemicals, Ahmadabad, India. All other chemicals used in the 
study were of highest analytical purity grade. The double 
distilled water is used throughout the study. 
 
Screening of Microemulsion Components 
The solubility of ebastine was determined in various oils, 
surfactants and cosurfactants. Drug powder was added in 
excess to each of the oils, surfactants and cosurfactants, 
thereafter subjected to vortexing. After vortexing, the 
samples were kept for 24 h at ambient temperature for 
attaining equilibrium. The equilibrated samples were then 
centrifuged at 3000 rpm for 20 min to remove the 
undissolved drug10. The aliquots of supernatant were filtered 
through 0.45 μm membrane filters and the solubility of 
Ebastine was determined by analyzing the filtrate 
spectrophotometrically (Shimadzu 1800, Japan) after 
dilution with methanol at 252 nm. Appropriately diluted 
solutions of oils in methanol were taken as blank. 
Construction of Pseudo-ternary phase Diagrams 
In order to find out the concentration range of components 
for the existing range of microemulsion, pseudo ternary 
phase diagrams were constructed using aqua- titration 
method at ambient temperature (25°C). Pseudo-ternary 
phase diagrams were constructed by Prosim software 11. 
Campul MCM EP selected as the oil phase. The blend of 
Labrasol with Tween 80 and blend of Propylene glycol with 
glycerol were selected as surfactant and co surfactant, 
respectively. Double distilled water was used as an aqueous 
phase. Various phase diagrams were prepared with weight 
ratios of surfactant to cosurfactant individual and blend.  For 
each phase diagram at a specific surfactant/cosurfactant 
weight ratio, the ratios of oil to the mixture of surfactant and 
cosurfactant were varied as 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 
8:2, 9:1. The mixtures of oil, surfactant and cosurfactant at 
certain weight ratios were diluted with water drop wise, 
under moderate magnetic stirring. After being equilibrated, 
the mixtures were assessed visually and determined as being 
microemulsion, crude emulsions or gels. No experimental 
attempt was made to distinguish between oil-in-water, water 
in-oil or bicontinuous type microemulsion. Gels were 
claimed for those clear and highly viscous mixtures that did 
not show a change in the meniscus after tilted to an angle of 
90°. 
Three phase diagrams were obtained for three different 
Smix individual ratios 1:1, 2:1, 3:1.The comparatively 
maximum microemulsion area was obtained in 2:1 Smix ratio. 
The selected Smix ratio was further studied by Smix blend, 
2(1:1):1, 2(1:1): 1(1:1). The Smix blend ratio which produced 
broader microemulsion region was selected for formulation 
optimization. This attempt was made to keep the surfactant 
concentration as low as possible in the ophthalmic 
formulation to avoid any associated toxicity. 
Optimization of Microemulsion by D-Optimal Mixture 
Design 
D-optimal mixture design (Design-Expert 7.0.0 (Stat-Ease 
Inc., Minneapolis, USA) was selected because the generalized 
variance of the estimates of the coefficients is minimized. 
The software selected a set of candidate points as a base 
design included factorial points (high and low level from the 
constraints on each factor, centers of edges, constraint plane 
centroids, axial checkpoint, and an overall center point). 
It is commonly used to reveal main effects and interaction 
effects between the independent variables of the 
experiment12. Moreover, the numbers of trials required are 
less. Twelve runs were carried out to optimize 
microemulsion formulation. Different design constraints, i.e. 
A (amount of oil), B (amount of Smix), and C (amount of 
water) were taken at high and low levels. The sum of A, B, 
and C were kept fixed at 100%. The effect of these 
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formulation variables was studied on the % Transmittance, 
globule size and viscosity. Validity of experimental design 
was confirmed by plotting a standard error of design graph. 
The probability value (α) for determination of statistical 
significance was set at 0.05, which indicated that a 
“hypothesis” theory would be rejected if their corresponding 
p-values were ≤ 0.0513. Models were selected on the basis of 
sequential comparison and lack of fit test. Significance of the 
models was further confirmed by statistical analysis. 
Response surface, contour plot, residual plot and overlay 
plots were constructed for the response variables. 
Preparation of Drug Loaded Microemulsion 
The D-optimal design suggested different combinations of 
oil, Smix, and water. The suggested quantity of oil and Smix was 
mixed using a magnetic stirrer to produce the oily phase, at 
this stage the Ebastine was dissolved in the oily phase. 
Finally aqueous phase was added drop wise to obtain drug 
loaded microemulsion formulation. 
Preparation of Drug Loaded Microemulsion Gel  
The optimized microemulsion has very low viscosity, which 
may restrict its topical application. To overcome this, gelling 
agents were incorporated into formulation. The ocular 
delivery improved by adding mucoadhesive polymer in 
formulation. The weight ratio of CMC (1%) and SH (1.5%) 
was found satisfactory based on proper gel formation. The 
former polymer used in commercial ocular formulations, as 
it has desirable mucoadhesive and a high retention time on 
the ocular surface and the latter one exhibit excellent 
viscoelastic, lubricating and water retention properties. The 
literature reveled that, this combination benefited with high 
viscosity under low friction conditions (between blinking) 
which stabilizes the tear film and low viscosity under high 
friction conditions (during the blinking) which reduces 
discomfort in animal as well as humans14.   
A specified amount of drug consisting of the chosen oil and 
Smix was magnetically stirred until the drug completely 
dissolved; microemulsion was prepared by adding aqueous 
phase. 1% CMC and 1.5% SH polymers dispersion was 
formed by suspending in water. The polymer dispersion kept 
for overnight to form viscous gel matrix. Prepared 
microemulsion and polymer dispersion was mixed in 1:1 
v/w ratio 15. Smooth viscous, transparent gel was formed. 
Characterization and Evaluation of Microemulsion  
Drug Excipient Compatibility 
Fourier-transform Infrared Spectroscopy (FTIR) Study 
IR spectroscopy was conducted using an FTIR 
spectrophotometer and the spectrum was recorded in the 
wavelength region of 4000– 400 cm−116, 17, 18. The procedure 
consisted of dispersing the samples in KBr, thus avoiding 
solid transition possibly inducing by extended grinding. The 
spectrums were scan at a resolution of 0.15 cm−1 and scan 
speed 20 scan/sec. The Infra-Red spectra’s of pure Ebastine 
and optimized formulation were obtained on Fourier 
Transform Infrared Spectrophotometer in order to detect the 
existence of a possible interaction between drug and 
excipients. 
Measurement of pH  
For optimized formulation, pH was measured using pH 
meter which was previously calibrated using standard 
buffers of pH 4 and pH 7 as per the established procedure16, 
17, 18. 
 
Measurement of Refractive Index  
After administration of eye drops, possible impairments of 
vision or discomfort to the patient is detected by refractive 
index measurements. Refractive index proved the 
transparency of formulation. The refractive index of the 
system was measured by Abbe Refractometer (RICO, Model 
RSR-1) by placing one drop of the formulation on the slide in 
triplicate and compared it with water16, 17, 18. 
Measurement of Osmolarity 
Evaluation of osmolarity using an osmometer is of vital 
importance for physiological acceptance of the formulation 
by ocular tissues16, 17, 18. Osmolarity of optimized formulation 
measured using Osmometer (Advanced Instruments Inc., 
USA; Model 3250). 
Measurement of Surface Tension 
Surface tension determination ensures the uniform 
spreading of the formulation on the corneal surface16, 17, 18. 
Tensiometer (Kruss Tensiometer; Dimensions: 19.900 
mm*0.200mm*10.00mm, Model K12PSS) was employed for 
the determination of surface tension. 
Droplet size, Zeta potential and Viscosity measurement  
The droplet size of the microemulsion was determined by 
photon correlation spectroscopy (which analyzes the 
fluctuations in light scattering due to the Brownian motion of 
the particles) using a Malvern zeta sizer (Nano ZS, Malvern 
instruments, UK), Zeta sizer able to measure sizes between 
10 and 5000 nm. The measurements were performed at 25°C 
at a 90° angle 19. Each size value reported was the average of 
at least three independent measurements. Samples were 
suitably diluted with double distilled filtered water to avoid 
multi-scattering phenomena and then placed in quartz 
cuvettes. The real and imaginary refractive indexes were set 
at 1.59 and 0.0, respectively. Zeta Potential was determined 
by Zeta sizer (Malvern instruments UK) using clear 
disposable zeta cell and filed strength of 20 V/cm was 
employed. The electrophoretic mobility was converted into 
to the zeta potential19. The viscosity of microemulsion was 
determined by Ostwald Type Capillary viscometer at room 
temperature20. 
Drug Content 
0.5 ml optimized microemulsion formulation (1% w/v) 
containing drug equivalent to 5 mg was extracted with 
methanol followed by further appropriate dilution with 
methanol and the drug content was determined using UV 
spectrophotometer (Shimadzu 1800, Japan) at 252 nm in the 
formulation. 
Transmission Electron Microscopy  
To study the microstructures of microemulsion, transmission 
electron microscopy is the most important technique as it 
directly produces high-resolution images. It can capture any 
co-existent structure and microstructural transitions21. The 
morphology of formulation was performed using (Technai-
20, Phillips, Holland, Electron source: LaB6, Tungsten 
Filament) A drop of sample was placed onto a carbon coated 
grid on a single tilt sample holder to form a thin liquid film. 
The excess solution was removed followed by negative 
staining with 1% phophotungstic acid. The sample was 
examined and simultaneously photographed at an 
accelerating voltage with point resolution 0.27nm and 
magnification up to 25x to 7, 50,000x. 
 
 
Mehetre et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):386-397 
ISSN: 2250-1177                                                                                   [389]                                                                                     CODEN (USA): JDDTAO 
In Vitro Drug Release Study 
The optimized microemulsion and microemulsion gel 
formulation was evaluated for drug release. The in vitro drug 
release study was carried out using the dialysis bag method. 
(Molecular weight 12–14 kDa) 22 23. Methanolic Phosphate-
buffered saline pH 7.4 was used as release medium. The 
system was maintained at 32 ± 0.50C to mimic conditions eye 
surface temperature with continuous stirring on magnetic 
stirrer at 150 rpm. The samples were collected periodically 
until 24hr. Ebastine content in the receptor chamber was 
determined by spectrophotometricaly. Sink conditions were 
maintained in the receptor compartment during in vitro 
release studies. Each sample analysis was performed in 
triplicate. 
Sterility Testing 
Sterility test was performed to examine the growth of 
bacteria or fungus. The optimized microemulsion 
formulation was sterilized using membrane filtration unit by 
passing the formulation through 0.22 μm membrane filter 
under aseptic conditions24. The media used to detect aerobic 
and anaerobic bacteria is fluid thioglycollate media and 
soyabean casein digest media is used to detect fungal 
organisms. For positive control aerobic bacteria 
Staphylococcus aureus and fungal organism Candida albicans 
were inoculated into fluid thioglycollate media and soyabean 
casein digest media respectively. The optimized formulation 
was incubated in an incubator at 37±10 C for a period of 14 
days using both the medias. The gelling agent incorporated 
into microemulsion system in aseptic cabinet in between 
burners to avoid further possible contamination. 
Accelerated Stability Tests by Centrifugation Stress Test 
Stress stability study of the microemulsion sample was 
carried out by subjecting it to centrifugation. The 
formulation was centrifuged at 9,000 rpm for 20 min by 
Centrifuge (Make Remi) and examined for phase 
separation25. 
RESULTS AND DISCUSSION 
Preliminary Screening of Microemulsion Components by 
Solubility Study  
Amongst various oils tested, Ebastine showed low solubility 
in all oils except for Campul MCM EP (28.5 ± 0.2 mg/ ml). 
Campul MCM EP is a mono-diglyceride of medium chain fatty 
acids (mainly caprylic and capric). After selection of Campul 
MCM EP as the oil phase, the goal was to identify the 
surfactant which shows the highest solubilization capacity 
for the drug. Ebastine shown maximum solubility in Labrasol 
(23.1 ± 0.3mg/ml) followed by Tween 80 (19.8 ± 0.1mg/ ml). 
Therefore, blend of Labrasol and tween 80 was selected as 
the surfactant for microemulsion formulation. Amongst 
cosurfactant tested, maximum solubility in propylene glycol 
(18.2 ± 0.1mg/ml) followed by alcohols. Amongst various S 
mix blends, propylene glycol, isopropyl alcohol and ethanol 
forms transparent system with 98.21%T, 99.01%T, and 
99.17% T respectively compared to other tested 
cosurfactants with selected surfactant. Due to ocular 
compatibility and volatility issue, selection of any alcohol as 
microemulsion component was prohibited. Therefore, blend 
of propylene glycol and glycerol was selected as the co-
surfactant for microemulsion formulation. Moreover, 
glycerol will help in maintaining osmolarity of formulation. 
Figure 1 exhibited comparative account for solubility of drug 
in various components of microemulsion formulation. 
Various cosurfactants were screened for solubility as well 
miscibility with a surfactant. The toxicity of nonionic 
surfactants is generally lesser than ionic surfactants, besides 
they have lower critical micelle concentration (CMC) and 
offer better in vivo stability of o/w microemulsion dosage 
forms. Therefore the screening of surfactant was done from 
amongst the nonionic surfactants only. 
 
     
Figure 1: Solubility profile of drug in various Oils, Surfactants and Co surfactants 
 
Construction of Pseudo-ternary Phase Diagram  
Initially, based on the results of maximum solubility, various 
pseudo ternary phase diagrams were constructed employing 
Campul MCM EP (Oil), Labrasol & Tween 80 (surfactants 
blend) and propylene glycol & glycerol (co-surfactant blend) 
for identifying the maximal region for formation of the 
thermo-dynamically stable microemulsion. Figure 2A and 2B 
illustrated pseudo ternary phase diagram for Smix individual 
system and Smix blend system respectively. Among the 
various combinations of individual and blend of surfactants 
and cosurfactants (i.e. 1:1, 2:1, 3:1) explored. The maximal 
region for microemulsion was observed at the ratio of 2:1 
Smix blend system as compared to same ratio with Smix 
individual system. An o/w microemulsion region was found 
towards the water-rich apex of the phase diagram. As the 
surfactant concentration was increased in the S mix ratio, a 
higher microemulsion region was observed. The probable 
reasons are a reduction of the interfacial tension by 
surfactant and increased the fluidity of the interface by 
cosurfactant.
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Figure 2 (A): Pseudo Ternary diagrams of Oil: Smix individual system (1:1), (2:1), (3:1) 
 
 
Figure 2 (B): Pseudo Ternary diagrams of Oil: Smix blend system 2(1:1):1, 2(1:1): 1(1:1). 
 
Optimization of Ebastine Microemulsion using D-
Optimal Mixture Design 
D-optimal mixture experimental design was applied in the 
present study. Campul MCM EP (X1), Smix (X2), and water 
(X3) were chosen as formulation variables and Globule size 
(nm) (Y1), Viscosity (cp) (Y2) and Transmittance (%) (Y3) 
were selected as response variables. The data obtained from 
globule size (response Y1), viscosity (response Y2), and 
transmittance (response Y3) was analyzed using Design 
Expert® Software. The polynomial equations comprise the 
coefficients for intercept, main first-order effects, interaction 
term. The value of the coefficients exhibits the effect of these 
variables on the response. A positive sign of coefficient 
indicates a synergistic effect while negative term indicates an 
antagonistic effect on the response. The data summarized in 
Table 1. After generating the polynomial equations through 
MLRA (Multiple linear regression analysis) relating the 
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dependent and independent variables, mixture components 
were optimized for the responses. The values of all the 
responses were fitted to models viz linear, quadratic, special 
cubic and cubic model where the best fit model was found to 
be cubic model for all the responses as compared to other 
models (Table 2). R2 values were reported resemble to unity 
indicating the high predictive ability of Response Surface 
Methodology (RSM) of underlying study. Further, the higher 
values (>4) of “Adequate Precision” indicate adequate signal. 
Figure 3A, 3B, 4A, 4B and 5A, 5B shows contour, 3D response 
curve for dependent variables viz globule size (nm), viscosity 
(cps) and transmittance (%) respectively. It can be observed 
from the response variables plots of Globule size that as the 
concentration of oil increases, globule size also increases 
while the concentration of Smix increase then globule size 
decreases. It can be observed from the response variables 
plots of viscosity that as the concentration of Smix increases 
and decrease in amount of water, viscosity increases. It can 
be observed from the response variables plots of 
transmittance that as the concentration of oil increases % 
transmittance decreases and Smix increases % transmittance 
increases. Further, linear correlation was found analogous 
for actual response and predicated response (Figure 3C, 4C, 
5C). The reliability of these response surfaces was also 
confirmed by the corresponding residual plot between the 
experimental run and the internally studentized residuals for 
all response variables, as shown in Figure 3D, 4D, 5D. The 
vertical distribution of the internally studenized residuals 
was in line from top to bottom under the completely 
randomized run. These findings revealed that all points fall 
within a confidence interval of 95 %. 
 
Table 1: Coefficient of Cubic equation for each independent variable 
Coefficient Globule size (nm) Transmittance (%) Viscosity (cps) 
A(Oil) +12332.37 -17.42 +319.48 
B(S mix) -183.07 +96.87 +0.16 
C(Water) +395.14 +98.00 -9.28 
AB -21162.35 +222.24 -528.76 
AC -20873.16 +188.96 -549.36 
BC +267.36 +9.88 +29.37 
ABC +19659.51 -211.96 +512.18 
AB (A-B) -11469.5 +122.26 -338.12 
AC (A-C) -9475.61 +65.83 -274.17 
BC(B-C) +991.69 +12.02 +23.55 
 
Table 2: Summary of regression analysis for all response 
Model Std. Dev. R-Squared 
Adjusted R-
Squared 
Predicted R-
Squared 
Remark 
Response 1 Globule size(nm) 
Linear 41.60808297 0.837278282 0.8011179 0.715878822  
Quadratic 32.84677275 0.932394153 0.876055946 0.63422757  
Special Cubic 14.55714352 0.988934528 0.975655962 0.936588798  
Cubic 1.573384878 0.999948293 0.999715613 0.881835238 Suggested 
Response 2 Viscosity (cps) 
Linear 0.356569823 0.965192595 0.957457616 0.941721624  
Quadratic 0.364390049 0.975766049 0.955571089 0.933770144  
Special Cubic 0.392523532 0.976566273 0.948445801 0.904700682  
Cubic 0.321333363 0.993718236 0.9654503 0.954526667 Suggested 
Response 3 Transmittance (%) 
Linear 0.438370154 0.65729547 0.581138908 0.327795929  
Quadratic 0.476286834 0.730298239 0.505546771 -0.520492351  
Special Cubic 0.459194362 0.791090361 0.540398794 -0.908508779  
Cubic 0.024307431 0.999765845 0.998712147 0.464988912 Suggested 
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Figure 3: Response variable Globule size (Y1) 
A. Contour plot B. Surface response curve C. Predicted Vs. Actual response and D. Residual Vs. run 
  
  
Figure 4: Response variable Viscosity (Y2) 
A. Contour plot B. Surface response curve C. Predicted Vs. Actual response and D. Residual Vs. run 
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Figure 5: Response variable Transmittance (Y3) 
A. Contour plot B. Surface response curve C. Predicted Vs. Actual response and D. Residual Vs. run 
 
Experimental Validation of Design Space  
Experimental validation of DoE trials for formulation 
variables was undertaken by formulation and 
characterization of microemulsion formulation at the check 
point batch suggested by the software. Figure 6 shows the 
overlay plot displaying the design space and optimized 
parameters as check point suggested by DoE software to 
obtain the desired responses. The observed values were 
comparable with the predicted values establishing the 
reliability of the optimization procedure as shown in Table 3. 
Calculated percentage prediction error was found to be less 
than 5 percent, confirming the validity of D- optimal mixture 
design for microemulsion formulation optimization. 
  
 
Figure 6: Overlay plot 
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Table 3: Checkpoint analysis of optimized formulation 
Error (%) = (predicted value – experimental value)/ predicted value × 100. 
Data expressed were of mean ±SEM (n=3) 
Characterization and Evaluation of Microemulsion 
Drug–Excipient Compatibility  
FTIR studies were carried out for pure drug alone and optimized formulation. The all characteristic peaks of pure ebastine were 
found in the optimized formation, suggested that there is no interaction between drug and excipients as shown in Figure 7A and 
7B. 
 
Figure 7 (A): FT-IR spectra of Pure Ebastine 
 
Figure 7 (B): FT-IR spectra of optimized formulation 
Measurement of pH  
Without much discomfort, the eye can tolerate pH of 6.5-8.0. 
The pH value of the developed microemulsion is 6.9 ± 0.12, 
which can be easily buffered by tear fluid (pH 7.2-7.4); 
consequently, it is adequate to apply to the eye without 
causing irritation, reflex tear and rapid tear blinking21. 
Measurement of Refractive Index  
Refractive index measurements detect possible impairment 
of vision or discomfort to the patient after administration of 
eye drops. Refractive index of tear fluid is 1.340 to 1.360. It is 
recommended that eye drops should have refractive index 
values not higher than 1.4764. The optimized formulation 
had refractive index values ranging from 1.369 ±0.04 which 
is resemble to the recommended values. 
Measurement of Osmolarity 
In formulating ophthalmic preparations consideration of 
isotonicity is of prime concern. The osmolarity of human tear 
film after prolonged eye closure is 288-293 mOsm/L and as 
eye is open, it progressively rises up to 302-318 mOsm/L21. 
An Osmolarity of optimized formulation was found to be 291 
± 0.301mOsm/L indicating appropriateness for ocular 
application. The glycerol used in said formulation performed 
dual role of imparting osmolarity to formulation and act as a 
cosurfactant also. 
Measurement of Surface Tension 
Ophthalmic formulation had the surface tension range at the 
surface to air interface of 34.3-70.9 mN/m. Formulations 
indicated for treatment red eye had surface tensions below 
normal tear26. The surface tension of the optimized 
microemulsion formulation was found to be 34.75 ±0.13 
mN/m. Low microemulsion surface tension ensures good 
Parameters Predicted value Experimental value % Error 
Globule Size (nm) 143.33 142 ± 0.16 0.92 
Viscosity(cps) 13.51 13.19± 0.121 2.36 
Transmittance (%) 99.09 99.79± 0.134 0.70 
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spreading effect on the conjunctive, cornea and mixing with 
precorneal film components, thereby improving contact 
between the drug and the conjunctival tissue. 
Droplet size, Zeta potential and Viscosity measurement 
The droplet size of prepared microemulsion formulation was 
found to be 142± 0.16 nm as shown in the Figure 8. The 
particle size that human eyes can tolerate is about 10 
micrometer21, indicating suitability of developed formulation 
for ocular use. The Polydispersity Index (PdI) was found to 
be well below 1.0 which confirms that the optimized 
microemulsion remains stable upon dilution. Zeta potential 
of prepared microemulsion formulations was found to be -
22.6 ± 0.39 mV as shown in the Figure 9 indicating that 
dilution does not have a significant impact on the 
microemulsion zeta potential. The Viscosity of optimized 
formulation was found to be 13.19 ± 0.121cps. The 
residential capacity of formulation at physiological site (eye) 
can be increased by adding gelling agent. 
  
 
 
Figure 8:  Globule size measurement of optimized formulation 
 
Figure 9: Zeta potential measurement of optimized formulatio 
Drug Content  
Microemulsion of Ebastine with blend of surfactant and 
cosurfactant were prepared by Phase Titration Method 
(Water titration) method. The percentage of drug content of 
optimized formulations was found to be 97.09 ± 0.12%  
Transmission Electron Microscopy  
The morphology of the droplets of optimized formulation 
measured using TEM showed spherical shape and uniform 
droplet size of optimized microemulsion. Because the loaded 
ebastine microemulsion globules are nanometric and 
morphologically spherical, they are not expected to cause 
ocular irritation. (Figure 10) 
 
Figure 10: Transmission electron microscopy (TEM) of 
optimized formulation 
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In vitro Drug Release Study 
It is difficult to mimic diffusion cell in vitro method with the 
real situation in vivo because cellulose membrane cannot 
exhibit the barriers of ocular multilayered epithelium as well 
as the constant volume of diffusion cell will not be able to 
eliminate the drug released by tear fluid turnover and 
nasolacrimal leakage.  This phenomenon affects the 
concentration gradient and the diffusion of the drug through 
the epithelium. Therefore, possibility exists that 
formulations would have a different release in vivo. 
In drug release profile (Figure 11), Maximum % Ebastine 
released from Microemulsion was found 89.19 ± 2.45% 
compared to Microemulsion gel 71.34 ± 2.34% within 8 hr. 
However, microemulsion gel was able to sustain the release 
of the remaining Ebastine for up to 24 h. It is found that drug 
release from Microemulsion is comparatively more than 
Microemulsion gel. This might be possible matrix effect on 
release of Ebastine due to incorporation of microemulsion in 
CMC and HA gel, a micro gel layer forms around the droplets 
that can hinder drug diffusion from the oil phase, so the rate 
and the amount of the released drug may decrease, while the 
release rate of the drug from microemulsion depends on the 
rate of diffusion of the drug from oil droplets. The possibility 
of the drug partition between the oil and the water phases in 
the presence of the surfactant positioned at the oil–water 
interface prior to release. Formulation provided the highest 
in vitro drug release with the ability of providing a sustained 
release over 24 hr, thus reducing frequency of application 
and improving patient compliance. But, microemulsion gel 
has better consistency for topical drug delivery. 
 
Figure 11: In vitro Release profile of optimized 
microemulsion formulation and microemulsion gel, Data 
expressed were of mean ± SEM 
Sterility Testing 
After specified incubation period, both fluid thioglycolate 
and soyabean casein digest media showed absence of 
turbidity which is a sign of growth of microorganisms in the 
test sample of the optimized formulation and negative 
control while the turbidity or growth was found in the 
sample for positive control of Staphylococcus aureus and 
Candida albicans.  
Accelerated Stability Tests by Centrifugation Stress Test 
Stress stability study of the microemulsion sample was 
carried out by subjecting to centrifugation. A formulation 
shows no sign of phase separation when subjected to 
centrifugation at 9,000 rpm for 20 minutes. Thus, it was 
concluded that the Microemulsion formulation was stable 
under stressful conditions.  
CONCLUSION 
Studies of equilibrium solubility were conducted in different 
oils, surfactants and co- surfactants to rationally optimize 
the formulation using D- optimum mixture design. The 
developed microemulsion was found in the limit of 
acceptable droplet size range for ocular use and presented 
physical stability. Physicochemical parameters like pH, 
osmolarity, isotonocity were found in the range which favors 
its ophthalmic suitability. The addition of the gelling agent 
increased the viscosity in comparison to parent 
microemulsion. The results of the release study indicated 
that formulation could prolong the precorneal retention 
owing to mucoadhesion by polymer. Hence, bioavailability at 
the site of action of said drug was found to be significantly 
increased. In conclusion, Ebastine microemulsion could be 
offered as a promising strategy for ocular drug delivery for 
allergic manifestation. These findings further warrant in vivo 
investigation. 
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